Search Publications

Search

per page

Found 336 matches. Displaying 1-10 Toggle highlighting of searched terms

[ 1-10 | Next ]

1. Guttman-Yassky E, Krueger JG   IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis   JOURNAL OF INVESTIGATIVE DERMATOLOGY 2018 JUL; 138(7):1467-1469 Full Text | PMID/PMCID

2. Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, Honda T, Shin JU, Lee H, Chou M, Estrada Y, Zheng XZ, Xu H, Krueger JG, Lee KH, Kabashima K, Guttman-Yassky E   Serum from Asian patients with atopic dermatitis is characterized by T(H)2/T(H)22 activation, which is highly correlated with nonlesional skin measures   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 2018 JUL; 142(1):324-328 Full Text | PMID/PMCID

3. Brunner PM, Israel A, Zhang N, Leonard A, Wen HC, Huynh T, Tran G, Lyon S, Rodriguez G, Immaneni S, Wagner A, Zheng XZ, Estrada YD, Xu H, Krueger JG, Paller AS, Guttman-Yassky E   Early-onset pediatric atopic dermatitis is characterized by T(H)2/T(H)17/T(H)22-centered inflammation and lipid alterations   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 2018 JUN; 141(6):2094-2106 Full Text | PMID/PMCID

4. Brunner PM, Suarez-Farinas M, He HL, Malik K, Wen HC, Gonzalez J, Chan TCC, Estrada Y, Zheng XZ, Khattri S, Dattola A, Krueger JG, Guttman-Yassky E   The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins (vol 7, 8707, 2017)   SCIENTIFIC REPORTS 2018 MAY 29; 8(?):? Article 8439 Full Text | PMID/PMCID

5. Chan TC, Hawkes JE, Krueger JG   Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment   THERAPEUTIC ADVANCES IN CHRONIC DISEASE 2018 MAY; 9(5):111-119 Full Text | PMID/PMCID

6. Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, On SJ, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG   Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 2018 MAY; 78(5):872-881.e6 Full Text | PMID/PMCID

7. Guttman-Yassky E, Krueger JG, Lebwohl MG   Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment   EXPERIMENTAL DERMATOLOGY 2018 APR; 27(4):409-417 Full Text | PMID/PMCID

8. Czarnowicki T, He HY, Wen HC, Hashim PW, Nia JK, Malik K, Estrada Y, Kimmel GW, Taliercio M, Krueger JG, Guttman-Yassky E   Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations   ALLERGY 2018 MAR; 73(3):713-723 Full Text | PMID/PMCID

9. Krueger JG, Brunner PM   Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities   EXPERIMENTAL DERMATOLOGY 2018 FEB; 27(2):115-123 Full Text | PMID/PMCID

10. Kim J, Tomalin L, Lee J, Fitz LJ, Berstein G, Correa-da Rosa J, Garcet S, Lowes MA, Valdez H, Wolk R, Suarez-Farinas M, Krueger JG   Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment   JOURNAL OF INVESTIGATIVE DERMATOLOGY 2018 FEB; 138(2):273-281 Full Text | PMID/PMCID

[ 1-10 | Next ]